Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Myovant Sciences Ltd.

http://myovant.com/

Latest From Myovant Sciences Ltd.

Keeping Track: Enhertu Brings Anti-HER2 Therapy To Lung Cancer; Novaliq Platform Supports Two Dry Eye NDAs

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Myovant Expects Gradual Growth For Myfembree With Endometriosis Approval

Myovant and partner Pfizer have expected a slow ramp for Myfembree in uterine fibroids and new indication endometriosis as they build awareness and grow the market for the GnRH antagonist class.

Approvals Business Strategies

ObsEva Ends Linzagolix Launch Plans, Casting Another Shadow Over Women's Health

The Swiss drug maker will initiate a "mass dismissal" and return rights to its lead drug candidate after the US FDA alerted the company to NDA deficiencies.

Gynecology & Urology Business Strategies

Dermavant Prepares For First Launch, Looking To Build A Blockbuster Psoriasis Brand

The Roivant-owned company's Vtama topical cream was approved by the US FDA with a broad label permitting use for mild, moderate or severe psoriasis.

Approvals Launches
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
  • Other Names / Subsidiaries
    • Myovant Sciences GmbH
    • Myovant Sciences, Inc.
UsernamePublicRestriction

Register